Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All HCQ studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19hcq.org COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Mortality 13% Improvement Relative Risk HCQ for COVID-19  Orioli et al.  LATE TREATMENT Is late treatment with HCQ beneficial for COVID-19? Retrospective 73 patients in Belgium Study underpowered to detect differences c19hcq.org Orioli et al., Diabetes & Metabolic Sy.., Dec 2020 Favors HCQ Favors control

Clinical characteristics and short-term prognosis of in-patients with diabetes and COVID-19: A retrospective study from an academic center in Belgium

Orioli et al., Diabetes & Metabolic Syndrome: Clinical Research & Reviews, doi:10.1016/j.dsx.2020.12.020
Dec 2020  
  Post
  Facebook
Share
  Source   PDF   All   Meta
HCQ for COVID-19
1st treatment shown to reduce risk in March 2020
 
*, now known with p < 0.00000000001 from 422 studies, recognized in 42 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
3,900+ studies for 60+ treatments. c19hcq.org
Small retrospective study of 73 diabetic patients in Belgium, 55 HCQ patients, showing HCQ RR 0.87, p = 1.0.
risk of death, 12.7% lower, RR 0.87, p = 1.00, treatment 8 of 55 (14.5%), control 3 of 18 (16.7%), NNT 47.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Orioli et al., 14 Dec 2020, retrospective, Belgium, peer-reviewed, 9 authors.
This PaperHCQAll
Clinical characteristics and short-term prognosis of in-patients with diabetes and COVID-19: A retrospective study from an academic center in Belgium
Laura Orioli, Thomas Servais, Leïla Belkhir, Pierre-François Laterre, Jean-Paul Thissen, Bernard Vandeleene, Dominique Maiter, Jean C Yombi, Michel P Hermans
Diabetes & Metabolic Syndrome: Clinical Research & Reviews, doi:10.1016/j.dsx.2020.12.020
Background and aims: We describe the characteristics and short-term prognosis of in-patients with diabetes and COVID-19 admitted to a Belgian academic care center. Methods: We retrospectively reviewed the data on admission from patients with known or newlydiagnosed diabetes and confirmed COVID-19. First, survivors were compared to non-survivors to study the predictive factors of in-hospital death in patients with diabetes. Secondly, diabetic patients with SARS-CoV-2 pneumonia were matched for age and sex with non-diabetic patients with SARS-CoV-2 pneumonia, to study the prognosis and predictive factors of in-hospital death related to diabetes. Results: Seventy-three diabetic patients were included. Mean age was 69 (±14) years. Women accounted for 52%. Most patients had type 2 diabetes (89.0%), long-term complications of hyperglycemia (59.1%), and hypertension (80.8%). The case-fatality rate (CFR) was 15%. Non-survivors had more severe pneumonia based on imaging (p 0.029) and were less often treated with metformin (p 0.036). In patients with SARS-CoV-2 pneumonia, CFR was 15.6% in diabetic (n ¼ 64) and 25.0% in non-diabetic patients (n ¼ 128), the difference being non-significant (p 0.194). Predictive factors of in-hospital death were elevated white blood cells count (HR 9.4, CI 1.50e58.8, p 0.016) and severe pneumonia on imaging (HR 25.0, CI 1.34 e466, p 0.031) in diabetic patients, and cognitive impairment (HR 5.80, CI 1.61e20.9, p 0.007) and cardiovascular disease (HR 5.63, CI 1.54e20.6, p 0.009) in non-diabetic patients. Conclusion: In this monocentric cohort from Belgium, diabetic in-patients with COVID-19 had mostly type 2 diabetes, prevalent hyperglycemia-related vascular complications and comorbidities including hypertension. In this cohort, the CFR was not statistically different between patients with and without diabetes.
References
Agarwal, Schechter, Southern, Crandall, Tomer, Preadmission diabetes-specific risk factors for mortality in hospitalized patients with diabetes and coronavirus disease 2019, Diabetes Care, doi:10.2337/dc20-1543
Al-Salameh, Lanoix, Bennis, Andrejak, Brochot et al., Characteristics and outcomes of COVID-19 in hospitalized patients with and without diabetes, Diabetes Metab Res Rev, doi:10.1002/dmrr.3388
Barron, Bakhai, Kar, Weaver, Bradley et al., Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: a whole-population study, Lancet Diabetes Endocrinol, doi:10.1016/S2213-8587(20)30272-2
Bastard, Rosen, Zhang, Michailidis, Hoffmann et al., Auto-antibodies against type I IFNs in patients with life-threatening COVID-19, Science, doi:10.1126/science.abd4585
Bennett, Tafuro, Mayer, Darlington, Wong et al., Clinical features and outcomes of adults with COVID-19: a systematic review and pooled analysis of the literature, Int J Clin Pract, doi:10.1111/ijcp.13725
Bramante, Ingraham, Murray, Marmor, Hoversten et al., Observational study of metformin and risk of mortality in patients hospitalized with covid-19, medRxiv, doi:10.1101/2020.06.19.20135095
Cariou, Hadjadj, Wargny, Pichelin, Al-Salameh et al., Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study, Diabetologia, doi:10.1007/s00125-020-05180-x
Caussy, Wallet, Laville, Disse, Obesity is associated with severe forms of COVID-19, Silver Spring, doi:10.1002/oby.22842
Chen, Chen, Gong, Rong, Ye et al., Clinical characteristics and outcomes of type 2 diabetes patients infected with COVID-19: a retrospective study, Engineering, doi:10.1016/j.eng.2020.05.017
Chen, Yang, Cheng, Chen, Peng et al., Clinical characteristics and outcomes of patients with diabetes and COVID-19 in association with glucose-lowering medication, Diabetes Care, doi:10.2337/dc20-0660
Crouse, Grimes, Li, Might, Ovalle et al., Metformin use is associated with reduced mortality in a diverse population with COVID-19 and diabetes, medRxiv, doi:10.1101/2020.07.29.20164020
Dennis, Mateen, Sonabend, Thomas, Patel et al., Type 2 diabetes and COVID-19erelated mortality in the critical care setting: a national cohort study in England, marchejuly 2020, Diabetes Care, doi:10.2337/dc20-1444
Fox, Ruddiman, Lo, Peterson, Dejoy 3rd R et al., The relationship between diabetes and clinical outcomes in COVID-19: a singlecenter retrospective analysis, Acta Diabetol, doi:10.1007/s00592-020-01592-8
Goyal, Choi, Pinheiro, Schenck, Chen et al., Clinical characteristics of covid-19 in New York city, N Engl J Med, doi:10.1056/NEJMc2010419
Guo, Li, Dong, Zhou, Zhang et al., Diabetes is a risk factor for the progression and prognosis of COVID-19, Diabetes Metab Res Rev, doi:10.1002/dmrr.3319
Holman, Knighton, Kar, 'keefe, Curley et al., Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes in England: a population-based cohort study, Lancet Diabetes Endocrinol, doi:10.1016/S2213-8587(20)30271-0
Nachega, Ishoso, Otokoye, Hermans, Machekano et al., Clinical characteristics and outcomes of patients hospitalized for COVID-19 in Africa: early insights from the democratic republic of the Congo, Am J Trop Med Hyg, doi:10.4269/ajtmh.20-1240
Pothen, Yildiz, Greef, Penaloza, Beauloye et al., Safe use of hydroxychloroquine and its combination with azithromycin in the context of Sars-CoV-2 outbreak: clinical experience in a Belgian tertiary center, Trav Med Infect Dis, doi:10.1016/j.tmaid.2020.101788
Pugliese, Vitale, Resi, Orsi, Is diabetes mellitus a risk factor for Corona Virus Disease 19 (COVID-19)?, Acta Diabetol, doi:10.1007/s00592-020-01586-6
Salinas, Blasco, Santo-Quiles, Lopez-Garrigos, Flores et al., Laboratory parameters in patients with COVID-19 on first emergency admission is different in non-survivors: albumin and lactate dehydrogenase as risk factors, J Clin Pathol, doi:10.1136/jclinpath-2020-206865
Sciensano, Belgian institue for public health
Seiglie, Platt, Cromer, Bunda, Foulkes et al., Diabetes as a risk factor for poor early outcomes in patients hospitalized with COVID-19, Diabetes Care, doi:10.2337/dc20-1506
Shi, Zhang, Jiang, Zhang, Hu et al., Clinical characteristics and risk factors for mortality of COVID-19 patients with diabetes in wuhan, China: a two-center, retrospective study, Diabetes Care, doi:10.2337/dc20-0598
Simonnet, Chetboun, Poissy, Raverdy, Noulette et al., High prevalence of obesity in severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) requiring invasive mechanical ventilation, Silver Spring, doi:10.1002/oby.22831
Simpson, Kay, Abbara, Bhalla, Chung et al., Radiological society of North America expert consensus statement on reporting chest CT findings related to COVID-19. Endorsed by the society of thoracic radiology, the American college of radiology, and RSNA -secondary publication, J Thorac Imag, doi:10.1097/RTI.0000000000000524
Singh, Gupta, Ghosh, Misra, Diabetes in COVID-19: prevalence, pathophysiology, prognosis and practical considerations, Diabetes Metab Syndr, doi:10.1016/j.dsx.2020.04.004
Solerte, 'addio, Trevisan, Lovati, Rossi et al., Sitagliptin treatment at the time of hospitalization was associated with reduced mortality in patients with type 2 diabetes and COVID-19: a multicenter, casecontrol, retrospective, observational study, Diabetes Care, doi:10.2337/dc20-1521
Vangoitsenhoven, Martens, Van Nes, Moyson, Nobels et al., Evidence of increased hospitalization rate for COVID-19 in community-dwelling patients with type 1 diabetes, Diabetes Care, doi:10.2337/dc20-1246
Wang, Fang, Zhu, Chen, Ding et al., Clinical characteristics of non-critically ill patients with novel coronavirus infection (COVID-19) in a Fangcang Hospital, Clin Microbiol Infect, doi:10.1016/j.cmi.2020.03.032
Williamson, Walker, Bhaskaran, Bacon, Bates et al., Factors associated with COVID-19-related death using OpenSAFELY, Nature, doi:10.1038/s41586-020-2521-4
Wu, Chen, Cai, Xia, Zhou et al., Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in wuhan, China, JAMA Intern Med, doi:10.1001/jamainternmed.2020.0994
Zeberg, The major genetic risk factor for severe COVID-19 is inherited from Neanderthals, Nature, doi:10.1038/s41586-020-2818-3
Zhang, Bastard, Liu, Pen, Velez et al., Inborn errors of type I IFN immunity in patients with life-threatening COVID-19, Science, doi:10.1126/science.abd4570
Zhang, Wei, Chen, Wan, Chen, Clinical analysis of risk factors for severe COVID-19 patients with type 2 diabetes, J Diabet Complicat, doi:10.1016/j.jdiacomp.2020.107666
Zheng, Peng, Xu, Zhao, Liu et al., Risk factors of critical & mortal COVID-19 cases: a systematic literature review and meta-analysis, J Infect, doi:10.1016/j.jinf.2020.04.021
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit